Program
JZP258
A development code. Also written as “JZP-258”, “Xywav” and “JZP258 (XYWAV)”.
Its studies are mostly in Narcolepsy · Idiopathic Hypersomnia, led by Jazz Pharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jazz Pharmaceuticals | 61 open or running | phase 4since Feb 25, 2021 | Jan 23, 2017 | Dec 23, 2027phase 3 · NCT07625280 |
Also a collaborator on its studies: jazz-pharmaceuticals-ireland-limited.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 23, 2017First study: phase 3 study in NarcolepsyFirst studyNCT03030599 · 201 enrolled · United States, Belgium, Czechia and more
- May 10, 2018Phase 3 study in Idiopathic HypersomniaNCT03533114 · 154 enrolled · United States, Belgium, Czechia and more
- Feb 25, 2021Phase 4 study in NarcolepsyNCT04794491 · 62 enrolled · United States
- May 12, 20232 phase 4 studiesNCT05869773, NCT05875974
- May 27, 2026Phase 3 study in NarcolepsyNCT07625280 · 120 planned · United States
Ahead
- Dec 23, 2027Primary completion: phase 3 study in NarcolepsyNCT07625280
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07625280Narcolepsy · United States | 3 | Recruiting | Dec 23, 2027 | 120 |
| NCT05875974Idiopathic Hypersomnia · United States, Canada | 4 | Completed | Mar 13, 2025 | 199 |
| NCT05869773Narcolepsy · United States, Belgium, France and more | 4 | Completed | Feb 25, 2025 | 155 |
| NCT04794491Narcolepsy · United States | 4 | Completed | Nov 15, 2022 | 62 |
| NCT03533114Idiopathic Hypersomnia · United States, Belgium, Czechia and more | 3 | Completed | Jun 12, 2020 | 154 |
| NCT03030599Narcolepsy · United States, Belgium, Czechia and more | 3 | Completed | Jan 24, 2019 | 201 |
How it is read
Names in the registry
- “JZP-258”, 3 entries
- “Xywav”, 1 entry
- “JZP258 (XYWAV)”, 1 entry
- “JZP258”, 1 entry
Codes read as this program: JZP258.
Conditions, from the studies’ own filings
- Narcolepsy, 4 studies
- Idiopathic Hypersomnia, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.